An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.

Trial Details

NCT ID
NCT06693336
Phase
PHASE2
Sponsor
ToLymph Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • SMS001
Locations (sample)
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Histopathological confirmed NSCLC
  • Stage Ib, IIa, IIb or IIIa (N2) for both dose escalation and dose confirmation (NOTE: Staging will be according to the AJCC 8th edition)
  • Age ≥18 years and suitable for lung cancer surgery
  • No prior chemotherapy and/or thoracic radiation therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →